Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus

The article contrasts healthcare ETFs: VanEck Pharmaceutical ETF (PPH) charges a higher 0.36% expense ratio vs Fidelity’s FHLC at 0.08%, while PPH offers a higher 1.9% dividend yield vs FHLC’s 1.2% (a +70 bps cash-flow advantage). Over 5 years, PPH delivered higher total growth, and it also shows lower 5-year max drawdown (-20.3% vs -17.7% reported for FHLC) and stronger recent performance with annualized returns of 14.4% (3-yr), 10.2% (5-yr), and 8.0% (10-yr). Despite FHLC’s broader 365-holding healthcare exposure and lower fee, the piece concludes PPH is the clearer winner for most periods and recommends leaning toward VanEck for continued outperformance.

Analysis

This is less a healthcare macro call than a vehicle-selection trade. The real edge is that PPH’s structure makes it a leveraged bet on a handful of mega-cap drug names, so any incremental flow into “quality defensives” will hit LLY, NVS, MRK, ABBV and JNJ more than the broader healthcare complex. FHLC’s lower fee matters most over 12-18 months; in a sideways equity tape, 28 bps of annual expense differential can quietly offset a meaningful chunk of the dividend yield gap.

The second-order issue is concentration risk disguised as safety. PPH looks defensive until one large constituent hits a pricing, patent, or clinical-data gap; then the ETF behaves like a single-name basket with poor diversification. That makes it more exposed to LLY-specific obesity-drug sentiment and to foreign-exchange/withholding drag on its non-U.S. holdings, while FHLC is better insulated if the market rotates toward broader healthcare beneficiaries such as managed care, services, and equipment rather than just pharma.

The contrarian view is that the recent outperformance of concentrated pharma may be near-term momentum, not a durable structural edge. If rates stay elevated and the market re-prices long-duration growth, the multiple support for high-quality pharma can narrow fast, and the lower-volatility, lower-fee broad basket can catch up. The thesis breaks if pharma leadership broadens further, LLY/MRK keep compounding without policy shocks, or the market enters a sustained risk-off regime where the highest-quality dividend stream wins regardless of fee drag.

Key Decisions for Investors

• Tactical 3-6 month trade: long PPH / short FHLC if you expect continued momentum in large-cap pharma leadership and retail/income chasing; keep sizing modest because the spread is effectively a concentration bet, not a pure sector beta bet.
• Core 6-18 month allocation: favor FHLC over PPH for defensive healthcare exposure if you want lower fee drag and less single-name risk; this is the better compounding vehicle if healthcare remains range-bound.
• If expressing a single-name view, prefer LLY or MRK over the ETF wrapper only when you have independent conviction on pipeline/earnings, because PPH already embeds heavy LLY exposure and the ETF structure dilutes any alpha from stock selection.
• Watch item: if LLY guidance or U.S. drug-pricing rhetoric weakens, expect PPH to underperform FHLC quickly; that is the cleanest falsifier for the relative-value long PPH thesis.
• For a low-risk hedge, consider a small long-FHLC / short-SPY pair as a defensive tilt rather than reaching for yield in PPH; this captures healthcare rotation without paying up for concentration.